POLICY STATEMENT

Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection

abstract

Palivizumab was licensed in June 1998 by the Food and Drug Administration for the reduction of serious lower respiratory tract infection caused by respiratory syncytial virus (RSV) in children at increased risk of severe disease. Since that time, the American Academy of Pediatrics has updated its guidance for the use of palivizumab 4 times as additional data became available to provide a better understanding of infants and young children at greatest risk of hospitalization attributable to RSV infection. The updated recommendations in this policy statement reflect new information regarding the seasonality of RSV circulation, palivizumab pharmacokinetics, the changing incidence of bronchiolitis hospitalizations, the effect of gestational age and other risk factors on RSV hospitalization rates, the mortality of children hospitalized with RSV infection, the effect of prophylaxis on wheezing, and palivizumab-resistant RSV isolates. This policy statement updates and replaces the recommendations found in the 2012 Red Book. Pediatrics 2014;134:415–420

Policy statements from the American Academy of Pediatrics (AAP) are designed to provide updated guidance for child health care topics, with an emphasis on evidence-based recommendations whenever possible. Policy statements are reviewed at least every 3 years and updated when appropriate. In following this procedure, the AAP Committee on Infectious Diseases (COID) has undertaken a systematic review of all recent and older peer-reviewed literature relating to the burden of respiratory syncytial virus (RSV) disease in infants and children, focusing on publications that delineate children at greatest risk of serious RSV disease and studies that define pharmacokinetics, safety, and efficacy. Detailed input regarding this guidance has been solicited from 21 committees, councils, sections, and advisory groups within the AAP, as well as organizations outside the AAP. Outside groups include the American College of Chest Physicians, American College of Emergency Physicians, American Thoracic Society, Emergency Nurses Association, National Association of Neonatal Nurses, National Association of Neonatal Nurse Practitioners, and Society of Hospital
Medicine. In addition, this review includes all data presented to the COID by the manufacturer of palivizumab.

As part of this deliberative review of palivizumab use, the COID judged the quality of the available data, as well as the impact of palivizumab prophylaxis to reach a unanimous consensus on guidance for the use of palivizumab in the United States. Cost was considered during deliberations by the COID and Bronchiolitis Guideline Committee, but the final guidance as presented here is driven by the limited clinical benefit derived from palivizumab prophylaxis.1–3

As detailed in the accompanying technical report,4 the benefit resulting from this drug is limited. Palivizumab prophylaxis has limited effect on RSV hospitalizations on a population basis, no measurable effect on mortality, and a minimal effect on subsequent wheezing.

This policy statement updates and replaces the most recent AAP recommendations for the use of palivizumab prophylaxis published in 2012 in the 29th edition of the Red Book.5 This policy statement offers specific guidance for the use of palivizumab on the basis of available evidence, as well as expert opinion. A detailed discussion of the foundation of the updated guidance for each category as well as the references for each section may be found in the accompanying technical report,4 and AAP guidelines for the diagnosis and management of bronchiolitis, which were published in 20066 (for which a revision is forthcoming).

The palivizumab package insert states: “Synagis is indicated for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease.”7 In the absence of a specific definition of “high risk” by the US Food and Drug Administration, the AAP has endeavored to provide pediatricians and other health care providers with more precise guidance for determining who is at increased risk since palivizumab was first licensed.8–11

The informed opinion of the COID and the Bronchiolitis Guidelines Committee, as well as others participating in the current statement, is that palivizumab use should be restricted to the populations detailed below.

**PRETERM INFANTS WITHOUT CHRONIC LUNG DISEASE OF PREMATURITY OR CONGENITAL HEART DISEASE**

Palivizumab prophylaxis may be administered to infants born before 29 weeks, 0 days’ gestation who are younger than 12 months at the start of the RSV season. For infants born during the RSV season, fewer than 5 monthly doses will be needed.

Available data for infants born at 29 weeks, 0 days’ gestation or later do not identify a clear gestational age cutoff for which the benefits of prophylaxis are clear. For this reason, infants born at 29 weeks, 0 days’ gestation or later are not universally recommended to receive palivizumab prophylaxis. Infants 29 weeks, 0 days’ gestation or later may qualify to receive prophylaxis on the basis of congenital heart disease (CHD), chronic lung disease (CLD), or another condition.

Palivizumab prophylaxis is not recommended in the second year of life on the basis of a history of prematurity alone.

Some experts believe that on the basis of the data quantifying a small increase in risk of hospitalization, even for infants born earlier than 29 weeks, 0 days’ gestation, palivizumab prophylaxis is not justified.

**PRETERM INFANTS WITH CLD**

Prophylaxis may be considered during the RSV season during the first year of life for preterm infants who develop CLD of prematurity defined as gestational age <32 weeks, 0 days and a requirement for >21% oxygen for at least the first 28 days after birth.

During the second year of life, consideration of palivizumab prophylaxis is recommended only for infants who satisfy this definition of CLD of prematurity and continue to require medical support (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) during the 6-month period before the start of the second RSV season. For infants with CLD who do not continue to require medical support in the second year of life prophylaxis is not recommended.

**INFANTS WITH HEMODYNAMICALLY SIGNIFICANT CHD**

Certain children who are 12 months or younger with hemodynamically significant CHD may benefit from palivizumab prophylaxis. Children with hemodynamically significant CHD who are most likely to benefit from immunoprophylaxis include infants with cyanotic heart disease who are receiving medication to control congestive heart failure and will require cardiac surgical procedures and infants with moderate to severe pulmonary hypertension.

Decisions regarding palivizumab prophylaxis for infants with cyanotic heart defects in the first year of life may be made in consultation with a pediatric cardiologist.

These recommendations apply to qualifying infants in the first year of life who are born within 12 months of onset of the RSV season.

The following groups of infants with CHD are not at increased risk of RSV infection and generally should not receive immunoprophylaxis:

- Infants and children with hemodynamically insignificant heart disease (eg, secundum atrial septal
defect, small ventricular septal defect, pulmonic stenosis, uncomplicated aortic stenosis, mild coarctation of the aorta, and patent ductus arteriosus)

- Infants with lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure
- Infants with mild cardiomyopathy who are not receiving medical therapy for the condition
- Children in the second year of life

Because a mean decrease in palivizumab serum concentration of 58% was observed after surgical procedures that involve cardiopulmonary bypass, for children who are receiving prophylaxis and who continue to require prophylaxis after a surgical procedure, a postoperative dose of palivizumab (15 mg/kg) should be considered after cardiac bypass or at the conclusion of extracorporeal membrane oxygenation for infants and children younger than 24 months.

Children younger than 2 years who undergo cardiac transplantation during the RSV season may be considered for palivizumab prophylaxis.

**CHILDREN WITH ANATOMIC PULMONARY ABNORMALITIES OR NEUROMUSCULAR DISORDER**

No prospective studies or population-based data are available to define the risk of RSV hospitalization in children with pulmonary abnormalities or neuromuscular disease. Infants with neuromuscular disease or congenital anomaly that impairs the ability to clear secretions from the upper airway because of ineffective cough are known to be at risk for a prolonged hospitalization related to lower respiratory tract infection and, therefore, may be considered for prophylaxis during the first year of life.

**IMMUNOCOMPROMISED CHILDREN**

No population based data are available on the incidence of RSV hospitalization in children who undergo solid organ or hematopoietic stem cell transplantation. Severe and even fatal disease attributable to RSV is recognized in children receiving chemotherapy or who are immunocompromised because of other conditions, but the efficacy of prophylaxis in this cohort is not known. Prophylaxis may be considered for children younger than 24 months of age who are profoundly immunocompromised during the RSV season.

**CHILDREN WITH DOWN SYNDROME**

Limited data suggest a slight increase in RSV hospitalization rates among children with Down syndrome. However, data are insufficient to justify a recommendation for routine use of prophylaxis in children with Down syndrome unless qualifying heart disease, CLD, airway clearance issues, or prematurity (<29 weeks, 0 days’ gestation) is present.

**CHILDREN WITH CYSTIC FIBROSIS**

Routine use of palivizumab prophylaxis in patients with cystic fibrosis, including neonates diagnosed with cystic fibrosis by newborn screening, is not recommended unless other indications are present. An infant with cystic fibrosis with clinical evidence of CLD and/or nutritional compromise in the first year of life may be considered for prophylaxis. Continued use of palivizumab prophylaxis in the second year may be considered for infants with manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest radiography or chest computed tomography that persist when stable) or weight for length less than the 10th percentile.

**RECOMMENDATIONS FOR TIMING OF PROPHYLAXIS FOR ALASKA NATIVE AND AMERICAN INDIAN INFANTS**

On the basis of the epidemiology of RSV in Alaska, particularly in remote regions where the burden of RSV disease is significantly greater than the general US population, the selection of Alaska Native infants eligible for prophylaxis may differ from the remainder of the United States. Clinicians may wish to use RSV surveillance data generated by the state of Alaska to assist in determining onset and end of the RSV season for qualifying infants.

Limited information is available concerning the burden of RSV disease among American Indian populations. However, special consideration may be prudent for Navajo and White Mountain Apache infants in the first year of life.

**DISCONTINUATION OF PALIVIZUMAB PROPHYLAXIS AMONG CHILDREN WHO EXPERIENCE BREAKTHROUGH RSV HOSPITALIZATION**

If any infant or young child receiving monthly palivizumab prophylaxis experiences a breakthrough RSV hospitalization, monthly prophylaxis should be discontinued because of the extremely low likelihood of a second RSV hospitalization in the same season (<0.5%).

**USE OF PALIVIZUMAB IN THE SECOND YEAR OF LIFE**

Hospitalization rates attributable to RSV decrease during the second RSV season for all children. A second season of palivizumab prophylaxis is recommended only for preterm infants born at <32 weeks, 0 days’ gestation who required at least 28 days of oxygen after birth and who continue to require
supplemental oxygen, chronic systemic corticosteroid therapy, or bronchodila-
tor therapy within 6 months of the start
of the second RSV season.

LACK OF THERAPEUTIC EFFICACY
OF PALIVIZUMAB
Passive antibody administration is not effective in treatment of RSV disease
and is not approved or recommended for this indication.

PREVENTION OF HEALTH
CARE-ASSOCIATED RSV DISEASE
No rigorous data exist to support palivizumab use in controlling out-
breaks of health care-associated dis-
ease, and palivizumab use is not
recommended for this purpose. Infants
in a neonatal unit who qualify for
prophylaxis because of CLD, pre-
maturity, or CHD may receive the
first dose 48 to 72 hours before
dischARGE to home or promptly after
dischARGE.
Strict adherence to infection-control
practices is the basis for reducing
health care-associated RSV disease.

RSV SEASONALITY
Because 5 monthly doses of palivizumab
at 15 mg/kg per dose will provide
more than 6 months (>24 weeks)
of serum palivizumab concentrations
above the desired level for most
children, administration of more
than 5 monthly doses is not recom-
manded within the continental United
States. For qualifying infants who re-
quire 5 doses, a dose beginning in
November and continuation for a total
of 5 monthly doses will provide pro-
tection for most infants through April
and is recommended for most areas
of the United States. If prophylaxis is
initiated in October, the fifth and final
dose should be administered in Feb-
ruary, which will provide protection
for most infants through March. If
prophylaxis is initiated in December,
the fifth and final dose should be ad-
ministered in April, which will provide
protection for most infants through
May.
Variation in the onset and offset of
the RSV season in different regions
of Florida may affect the timing of
palivizumab administration. Data from
the Florida Department of Health may
be used to determine the appropriate
timing for administration of the first
dose of palivizumab for qualifying
infants. Despite varying onset and
offset dates of the RSV season in dif-
f erent regions of Florida, a maximum
of 5 monthly doses of palivizumab should
be adequate for qualifying infants for
most RSV seasons in Florida.
Sporadic RSV infections occur through-
out the year in most geographic lo-
cations. During times of low RSV
prevalence (regardless of proportion
of positive results), prophylaxis with
palivizumab provides the least benefit
because of the large number of chil-
dren who must receive prophylaxis to
prevent 1 RSV hospitalization.

EFFECT OF PALIVIZUMAB
PROPHYLAXIS ON SUBSEQUENT
WHEEZING
Prophylaxis is not recommended for
primary asthma prevention or to reduce
subsequent episodes of wheezing.

SUMMARY OF GUIDANCE
● In the first year of life, palivizumab
prophylaxis is recommended for
infants born before 29 weeks,
0 days’ gestation.
● Palivizumab prophylaxis is not rec-
ommended for otherwise healthy
infants born at or after 29 weeks,
0 days’ gestation.
● In the first year of life, palivizumab
prophylaxis is recommended for pre-
term infants with CLD of prematurity,
defined as birth at <32 weeks, 0 days’
geration and a requirement for
>21% oxygen for at least 28 days
after birth.
● Clinicians may administer palivizumab
prophylaxis in the first year of life to
certain infants with hemodynamically
significant heart disease.
● Clinicians may administer up to
a maximum of 5 monthly doses of
palivizumab (15 mg/kg per dose)
during the RSV season to infants
who qualify for prophylaxis in the
first year of life. Qualifying infants
born during the RSV season may
require fewer doses. For example,
infants born in January would re-
ceive their last dose in March.
● Palivizumab prophylaxis is not rec-
ommended in the second year of
life except for children who re-
quired at least 28 days of supple-
mental oxygen after birth and who
continue to require medical
intervention (supplemental oxygen,
chronic corticosteroid, or diuretic
therapy).
● Monthly prophylaxis should be discon-
tinued in any child who experiences
a breakthrough RSV hospitalization.
● Children with pulmonary abnor-
mality or neuromuscular disease
that impairs the ability to clear
secretions from the upper airways
may be considered for prophylaxis
in the first year of life.
● Children younger than 24 months
who will be profoundly immuno-
compromised during the RSV
season may be considered for
prophylaxis.
● Insufficient data are available to
recommend palivizumab prophy-
laxis for children with cystic fibro-
sis or Down syndrome.
● The burden of RSV disease and
costs associated with transport
from remote locations may result
in a broader use of palivizumab
for RSV prevention in Alaska Native
population and possibly in selected other American Indian populations.

- Palivizumab prophylaxis is not recommended for prevention of health care-associated RSV disease.

COMMITTEE ON INFECTIOUS DISEASES, 2013–2014
Michael T. Brady, MD, FAAP – Chairperson, Red Book Associate Editor
Carrie L. Byington, MD, FAAP
H. Dele Davies, MD, FAAP
Kathryn M. Edwards, MD, FAAP
Mary Anne Jackson, MD, FAAP – Red Book Associate Editor
Yvonne A. Maldonado, MD, FAAP
Dennis L. Murray, MD, FAAP
Walter A. Orenstein, MD, FAAP
Mobeen H. Rathore, MD, FAAP
Mark H. Sawyer, MD, FAAP
Yvonne A. Maldonado, MD, FAAP

EX OFFICIO
Henry H. Bernstein, DO, MHCM, FAAP – Red Book Online Associate Editor
David W. Kimberlin, MD, FAAP – Red Book Editor
Sarah S. Long, MD, FAAP – Red Book Associate Editor
H. Cody Meissner, MD, FAAP – Visual Red Book Associate Editor

LIAISONS
Marc A. Fischer, MD, FAAP – Centers for Disease Control and Prevention
Bruce G. Gellin, MD, MPH – National Vaccine Program Office
Richard L. Gorman, MD, FAAP – National Institutes of Health

REFERENCES
8. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory


An error occurred in the policy statement from the American Academy of Pediatrics titled “Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection” published in the August 2014 issue of Pediatrics (2014;134[2]:415–420). On pages 417–418, the last sentence in the section titled Use of Palivizumab in the Second Year of Life should read: “A second season of palivizumab prophylaxis is recommended only for preterm infants born at <32 weeks, 0 days’ gestation who required at least 28 days of oxygen after birth and who continue to require supplemental oxygen, chronic systemic corticosteroid therapy, or diuretic therapy within 6 months of the start of the second RSV season.” Bronchodilator therapy has been removed as a consideration for prophylaxis in the second RSV season.

We regret this error.

doi:10.1542/peds.2014-2783

An error occurred in the article by Veres et al, titled “Duodenal Ulceration in a Patient With Celiac Disease and Plasminogen I Deficiency: Coincidence or Cofactors?” published in the November 2011 issue of Pediatrics (2011;128[5]:e1302–e1306; doi:10.1542/peds.2010-2251). On page e1302, the list of authors reads: “Gabor Veres, MD, PhD,a Ilma Korponay-Szabó, MD, PhD,b Erika Maka, MD,cd Tibor Glasz, MD, PhDe,d Petar Mamula, MD,f Maria Papp, MD, PhD,f Antal Dezsof, MD, PhD,f and Andras Arató, MD, Dsc”.

The list of authors should have read: “Gabor Veres, MD, PhD,a Ilma Korponay-Szabó, MD, PhD,b Erika Maka, MD,cd Tibor Glasz, MD, PhDe,d Petar Mamula, MD,f Maria Papp, MD, PhD,f Antal Dezsof, MD, PhDe,d Volker Schuster, MD,f Katrin Tefs, PhD,g and Andras Arató, MD, Dsc”.

The author affiliations should have included: “aChildren’s Hospital, University of Leipzig, Germany”.

doi:10.1542/peds.2014-2897

An error occurred in the article by Charach et al, titled “Interventions for Preschool Children at High Risk for ADHD: A Comparative Effectiveness Review” published in the May 2013 issue of Pediatrics (2013;131[5]:e1584–e1604; doi:10.1542/peds.2012-0974). Starting on page e1592, under the PATS heading within the Results section, this reads: “Methylphenidate improved core parent-rated and teacher-rated ADHD symptoms during the within-subject crossover titration phase with a mean optimal single dose of 0.7 + /− 0.4 mg/kg, and with a mean optimal total daily dose of 14.2 + /− 8.1 mg/kg/day.”

This should have read: “Methylphenidate improved core parent-rated and teacher-rated ADHD symptoms during the within-subject crossover titration phase with
Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection

COMMITTEE ON INFECTIOUS DISEASES AND BRONCHIOLITIS
GUIDELINES COMMITTEE

Pediatrics; originally published online July 28, 2014;
DOI: 10.1542/peds.2014-1665

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/early/2014/07/23/peds.2014-1665